Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    World Bank approves US$700 million loan for Jordan jobs

    July 2, 2026

    Mexico advances after 2-0 win over Ecuador in World Cup

    July 2, 2026

    Mexico advances after 2-0 win over Ecuador in World Cup

    July 2, 2026
    Tokyo AdvertiserTokyo Advertiser
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • Sports
    • Technology
    • Travel
    Tokyo AdvertiserTokyo Advertiser
    Home » OKRA.ai, an Envision Pharma Group Company, Appoints Dr. Yahya Anvar to Senior Leadership Position
    ACCESS Newswire

    OKRA.ai, an Envision Pharma Group Company, Appoints Dr. Yahya Anvar to Senior Leadership Position

    June 15, 2023
    Facebook Twitter Pinterest LinkedIn Telegram Tumblr Email

    PHILADELPHIA, PA / ACCESSWIRE / June 15, 2023 / OKRA.ai, an Envision Pharma Group (Envision) company, has appointed senior leader Dr. Yahya Anvar as Chief of AI Science & Insights to unleash the full potential of artificial intelligence (AI) and to further support the life sciences industry.

    Envision Pharma Group, Thursday, June 15, 2023, Press release picture

    “I am excited about continuing the innovative collaboration between Envision and OKRA.ai along with Yahya as a senior leader as it further solidifies our Envision commitment to the expansion of OKRA.ai and leadership in the AI and technical space,” shares Meg Heim, CEO of Envision Pharma Group. “His leadership is critical to our vision to accelerate the delivery of our compelling combination of technology-enabled capabilities and solutions to clients as we continue to strengthen our offerings across the product life cycle, but more importantly to support patients in their journey to health and wellness.”

    Anvar joined OKRA.ai in 2019, heading the Data Science team. During his tenure, he has led the development of AI solutions across OKRA.ai’s portfolio of products and services. Prior to joining the company, he served as the principal investigator of preclinical personalized medicine at Leiden University Medical Center. He has over 14 years of experience in the healthcare sector and is the author of over 30 peer-reviewed scientific articles. Anvar holds a PhD in Computational Biology from the faculty of Medicine at Leiden University, and an MSc in Bioinformatics and Artificial Intelligence from Brunel University.

    Anvar shares, “It is an absolute privilege to be leading the AI insights and science at Envision and pushing the boundaries of what AI has to offer to better patients’ outcomes. Making an impact through solutions that provide actionable, explainable insights is what we thrive for. There is no better time for new beginnings than today, and I’m so excited to be working with the Envision team to transform the industry as we know it.”

    Dr. Loubna Bouarfa, Head of AI & Innovative Platforms at Envision, shares, “It was a pleasure to work with Yahya; he has been an exceptional leader of the Data Science team at OKRA.ai. His role has now expanded to cover AI insights and scientific expertise across the entire Envision organization following our recent acquisition. I look forward to working with him in driving AI innovation and propelling Envision to new heights.”

    About Envision Pharma Group

    Founded in 2001, Envision Pharma Group is a leading global technology-enabled strategic solutions partner for the life sciences industry, working with over 200 pharma and biotech companies, including 18 of the top 20 pharmaceutical companies. Envision supports clients across the product life cycle through a comprehensive suite of services and industry-leading technology solutions that include artificial intelligence and natural language processing, commercialization and integrated strategic consulting, evidence-based scientific communications and engagement, HEOR/market access and data analytics, medical capabilities, and omnichannel solutions. Learn more at www.envisionpharmagroup.com.

    Contact Information:

    Colleen Carter
    Associate Director, Communications, Office of CEO
    colleen.carter@envisionpharma.com
    1 (508) 505 8856

    SOURCE: Envision Pharma Group

    .
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

    Related Posts

    Multi-Billion-Dollar Global Sports Brand U.S. Polo Assn. Earns Global Awards and Recognitions Across Business, Sport, and Content Categories

    June 30, 2026

    Pacific Avenue Capital Partners Announces Investment Committee Appointment, New AI Initiative, and Team Expansion

    June 26, 2026

    U.S. Polo Assn. Unveils Spring-Summer 2027 Collection at the 110th Edition of Pitti Immagine Uomo

    June 18, 2026

    U.S. Polo Assn. Palm Beaches Marathon Celebrates America’s 250th, Adds $17,000 in Prize Money as it Returns December 12-13, 2026

    June 11, 2026

    TruMerit and Credivera Issue First Verifiable Digital Credentials for Global Healthcare Professionals

    May 8, 2026

    How to Clear the Strait of Hormuz from the Air: UMag Solutions Launches F1Mag(R) – an Unmanned Solution for Rapid Naval Mine Detection and Anti-Submarine Warfare

    May 7, 2026
    Latest News

    World Bank approves US$700 million loan for Jordan jobs

    July 2, 2026

    AMMAN, JORDAN / MENA Newswire / – The World Bank approved a US$700 million loan…

    Mexico advances after 2-0 win over Ecuador in World Cup

    July 2, 2026

    Mexico advances after 2-0 win over Ecuador in World Cup

    July 2, 2026

    South Korea exports reach record US$102.25 billion in June

    July 2, 2026

    Harry Kane lifts England into World Cup round of 16

    July 2, 2026

    Japan new car sales rise 1.8% in first half of 2026

    July 2, 2026

    DR Congo Ebola cases rise to 1,307 with 377 deaths

    June 30, 2026

    South Korea tourist spending hits record in May

    June 29, 2026
    © 2026 Tokyo Advertiser | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.